<DOC>
	<DOCNO>NCT02408822</DOCNO>
	<brief_summary>Paclitaxel antiproliferative drug limit vascular intimal hyperplasia . Paclitaxel-coated balloon already indication treatment peripheral arterial disease . This randomize controlled trial design prove superiority drug-eluting balloon catheter ( Paclitaxel-coated balloon ) plain balloon catheter treatment stenosed autogeneous prosthetic vascular access , hemodialysis patient . The hypothesis use drug-eluting balloon improve post-interventional patency access , therefore , limit number day hospitalization maintenance hemodialysis vascular access .</brief_summary>
	<brief_title>Drug-Eluting Balloon Angioplasty Treatment Hemodialysis Vascular Access Stenosis ( DEBAVAS )</brief_title>
	<detailed_description>Introduction : Half patient hemodialysis vascular access present least one episode dysfunction within 1 year creation , mainly due intimal hyperplasia stenosis . Paclitaxel antiproliferative drug limit intimal hyperplasia vessel . Paclitaxel-coated balloon already indication treatment peripheral arterial disease . Main objective : To show use Paclitaxel-coated balloon treat stenosis vascular access improve post-interventional patency reduce number day hospitalization access maintenance hemodialysis vascular access . Hypothesis : Paclitaxel-coated balloon angioplasty ( PTX ) prolongs primary patency access treatment vascular access stenosis compare plain balloon angioplasty ( PBA ) ( standard treatment ) . Methodology : We design prospective , single-blinded , multicenter , randomize , control trial , aim enroll 120 patient . Patients diagnose stenosis dysfunctional vascular access line ( brachial-cephalic autogeneous fistula brachial-axillary prosthetic graft ) randomize either arm study completion successful pre-dilation standard plain balloon catheter . Randomization stratify accord type access ( brachial-cephalic autogeneous fistula brachial-axillary prosthetic graft ) . Primary outcome measure primary patency vascular access 12 month treatment . Secondary outcome measure primary patency 6 month , assisted-primary secondary patency 6 12 month , number re-interventions number day hospitalization re-intervention 12 month . Clinical significance : By prolong vascular access lifespan , Paclitaxel-coated balloon angioplasty limit morbidity cost vascular access maintenance hemodialysis patient .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<criteria>Patient must 18 year age old time sign date informed consent ( upper age limit ) , male female . Patient must vascular access hemodialysis ( type : brachialcephalic autogeneous fistula brachialaxillary prosthetic graft ) Patient must dysfunction vascular access , define : dialysis session last &gt; 4 hour and/or access flow &lt; 400ml/min fistula &lt; 600ml graft , 20 % decrease access flow monitor dialysis Duplex ultrasound scan , and/or dialysis recirculation and/or thrill perceive and/or pulsatile vascular access and/or bleed increase bleeding time puncture A stenosis &gt; 50 % venous line must diagnose initial fistulogram A successful plain balloon angioplasty stenosis , define residual stenosis &lt; 30 % control angiogram , without dissection indication use stent additional surgical procedure , must complete inclusion . Pregnant nursing woman , plan become pregnant study . Patient hyperkalemia &gt; 6,5 mmol/L EKG modification acute cardiac insufficiency time inclusion Vascular access instent restenosis Initial fistulogram show stenosis Initial fistulogram show indication open surgical intervention Control fistulogram ( plain balloon angioplasty ) show indication stenting open surgical intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>